Trials / Completed
CompletedNCT04422561
Prophylactic Ivermectin in COVID-19 Contacts
Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contact for Patient With COVID-19
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 340 (actual)
- Sponsor
- Zagazig University · Other Government
- Sex
- All
- Age
- 16 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
asymptomatic family close contact of confirmed COVID -19 patient will receive prophylactic ivermectin and will be followed up for 14 days for any symptoms \& diagnosis of COVID -19
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ivermectin Tablets | two doses 72 hours apart |
Timeline
- Start date
- 2020-05-31
- Primary completion
- 2020-07-14
- Completion
- 2020-07-27
- First posted
- 2020-06-09
- Last updated
- 2020-08-27
- Results posted
- 2020-08-27
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT04422561. Inclusion in this directory is not an endorsement.